• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Breakthrough nonsurgical treatment for canine mast cell tumors is now on the market

August 17, 2021
dvm360 Staff
dvm360, dvm360 October 2021, Volume 52, Issue 10

Virbac’s tigilanol tiglate injections (Stelfonta) has been approved by the FDA for treatment of the most common type of skin cancer in dogs.

Tigilanol tiglate injection (Stelfonta; Virbac) for treating canine mast cell tumors is now available in veterinarian clinics throughout the United States as an alternative to surgery. The therapy was approved by the FDA in November 2020 for the treatment of nonmetastatic, cutaneous mast cell tumors anywhere on a dog's body and nonmetastatic, subcutaneous mast cell tumors located in the lower parts of dogs' legs.

According to the Morris Animal Foundation, cancer is the leading cause of death in dogs over age 2. Mast cell tumors are the most common type of skin cancer in dogs and often appear as a nodule on or just underneath the skin. Although typical treatment options include surgery, chemotherapy and radiation, these treatments may not be appropriate for every dog.

According to Virbac, tigilanol tiglate is a biologically active pharmaceutical ingredient discovered by Australian company Qbiotics in the seed of the blushwood tree native to the rainforest of North Queensland. Injected directly into the tumor, tigilanol tiglate works by activating the local innate immune system with destruction of the tumor cells and tumor blood supply, leading to tumor destruction. Tigilanol tiglate also promotes complete healing of the typical tissue deficit left after tumor removal with minimal scar formation. Although sedation is not usually required, it may be necessary to administer this injection therapy safely and accurately.

According to Virbac, this therapy can induce a substantial but transitory local inflammatory reaction which may result in pain, bruising, and swelling. Therefore, as with surgery, pain control medication is recommended.

Among dogs treated with tigilanol tiglate in the registration clinical trial conducted in the United States, 75% of mast cell tumors achieved a complete response (complete tumor removal) of the injected tumor with just 1 treatment, and nearly all of the tumor sites healed within 6 weeks. According to Virbac, some wounds can be more extensive and may require additional management and healing time. In this same controlled clinical trial, interventions such as a collar or bandages to manage wounds were minimal and only required in 5 of 117 cases.

Advertisement

Since tigilanol tiglate received approval from the FDA, roughly 88% of United States veterinarians polled who have used the therapy to treat canine mast cell tumors reported satisfactory experiences. It has also received approval from regulatory agencies in Australia, Europe and the United Kingdom for the treatment of canine mast cell tumors.

Tigilanol tiglate may cause extensive wound formation at the tumor site, including cellulitis and severe tissue sloughing that may require additional management and healing time. The most common adverse reactions seen in the clinical trial were wound formation, injection site pain, lameness in the treated limb, vomiting, diarrhea, hypoalbuminemia, and injection site bruising. Sedation of the dog may be necessary to administer tiglate tigilanol safely and accurately, and to decrease the chance of accidental self-injection that may cause local inflammation and wound formation. The safe use of tigilanol tiglate has not been evaluated in dogs younger than 3.5 years old.

Reference

Virbac announces FDA approval of new cancer treatment for dogs derived from Australian rainforest plant. News release. August 16, 2021; Virbac. Accessed August 16, 2021. https://www.prnewswire.com/news-releases/virbac-announces-fda-approval-of-new-cancer-treatment-for-dogs-derived-from-australian-rainforest-plant-301355529.html

download issueDownload Issue: dvm360 October 2021

Related Content:

OncologyProductsTechnologyMedicalDermatologyClinicalPractice OperationsTechniciansAssociatesdvm360 October 2021
CE: Why tapeworms matter
CE: Why tapeworms matter
Freshpet and Petco partner launch fresh pet food subscription
Freshpet and Petco partner launch fresh pet food subscription
VHMA announces latest class of CVPMs
VHMA announces latest class of CVPMs

Advertisement

Latest News

CE: Why tapeworms matter

Freshpet and Petco partner launch fresh pet food subscription

AAHA Con heads to San Diego

VHMA announces latest class of CVPMs

View More Latest News
Advertisement